Forest Laboratories (FRX)
Forest Laboratories Cash and ST Investments: 2.427B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
FRX Cash and ST Investments Rankings
| Overall | 93rd percentile | 263 of 4365 |
| Sector | 96th percentile | 18 of 504 in Healthcare |
| Industry | 94th percentile | 2 of 39 in Drug Manufacturers - Other |
FRX Cash and ST Investments Range, Past 5 Years
| Minimum | 1.531B | Jun 2007 |
| Maximum | 3.851B | Mar 2011 |
| Average | 2.560B |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these FRX related companies
FRX News
Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
May 25, 12:32PM Street Insider
May 25, 12:32PM Street Insider
Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012
May 14, 8:00AM Business Wire
May 14, 8:00AM Business Wire
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest ROE
Apr 24, 3:44AM Benzinga
Apr 24, 3:44AM Benzinga
Ironwood (IRWD), Forest (FRX) Repot Three-Month Extension on FDA Linaclotide Review
Apr 23, 6:26AM Street Insider
Apr 23, 6:26AM Street Insider
Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012
Apr 23, 2:30AM Business Wire
Apr 23, 2:30AM Business Wire
Cantor Fitzgerald Maintains a 'Buy' on Forest Laboratories (FRX); Raising PT and Estimates
Apr 18, 12:55PM Street Insider
Apr 18, 12:55PM Street Insider
UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT for Forest Laboratories
Apr 18, 11:07AM Benzinga
Apr 18, 11:07AM Benzinga
Market Wrap Video + Additions to Watch List http://stks.co/3OUz including: $CHS $CROX $DECK $FRX $FSLR $MIPS $SRZ $TRMB
about 41 days ago by StockTiger
about 41 days ago by StockTiger
Forest Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Apr 18, 9:00AM Seeking Alpha
Apr 18, 9:00AM Seeking Alpha
Market Wrap Video + Additions to Watch List http://stks.co/3O64 including: $CHS $CROX $DECK $FRX $FSLR $MIPS $SRZ $TRMB
about 41 days ago by StockTiger
about 41 days ago by StockTiger
$FRX Provides Fiscal Year 2013 EPS Guidance in the Range of $0.90-$1.05 Per Share. http://stks.co/3NIN
about 42 days ago by abubnic
about 42 days ago by abubnic
$FRX reports Bystolic sales @ $96.9M, Savella sales @ $25.3M. R&D spending: $213.9M
about 42 days ago by abubnic
about 42 days ago by abubnic
$FRX Q4 Earnings: Adjusted EPS 78c vs consensus of 70c. Revenue: $1.06B vs consensus of $1.02B
about 42 days ago by abubnic
about 42 days ago by abubnic
$FRX flashing golden cross. Possibly setting up a bull flag. http://stks.co/3G8v
about 51 days ago by tradewithpete
about 51 days ago by tradewithpete
News related to $FRX, currently +0.5% since open: 'Fight over hypertension pill leads to lawsuit' http://stks.co/2r04
about 76 days ago by TradeBot
about 76 days ago by TradeBot
$FRX reports 2nd set of positive results in Phase III trials of anti-depressant drug, Levomilnacipran. http://stks.co/2hug
about 83 days ago by abubnic
about 83 days ago by abubnic
News related to $FRX, currently -0.2% since open: 'Ironwood Pharma falls as analyst cuts rating' http://stks.co/2g6B
about 85 days ago by TradeBot
about 85 days ago by TradeBot
http://stks.co/2arQ upwards earnings revisions Post Earnings Revision Drift $BIIB,$DV,$FRX,$LSCC,$XLNK (run 2 weeks ago)
about 91 days ago by secretbonus
about 91 days ago by secretbonus
$FRX get EU appro for Colobreathe cystic fibrosis inhalation treatment for chronic lung infection in kids >6yrs old. http://stks.co/2ZWP
about 92 days ago by abubnic
about 92 days ago by abubnic
Listen to $FRX Forest Laboratories, Inc. at Citi Global Health Care Conference - live at 09:00 AM, ondemand after - http://stks.co/2ZUN
about 92 days ago by earningscast
about 92 days ago by earningscast
WSJ| FDA Panel Supports Approval Of $FRX Lung Drug Aclidinium. http://stks.co/2Yvo
about 93 days ago by abubnic
about 93 days ago by abubnic
$FRX and Almirall: FDA Advisory Committee Recommends Approval of Aclidinium Bromide for Treatment of COPD. http://stks.co/2Yvl
about 93 days ago by abubnic
about 93 days ago by abubnic
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| FRX | 33.38 | +0.05 | +0.15% | 8.863B |
| FRT | 98.59 | -0.60 | -0.60% | 6.277B |
| FRED | 14.12 | +0.12 | +0.86% | 525.69M |
| FRD | 10.08 | +0.01 | +0.10% | 68.54M |
| FRC | 32.85 | -0.10 | -0.30% | 4.272B |
| FRBK | 1.91 | -0.05 | -2.55% | 49.60M |
| FRA | 14.27 | -0.08 | -0.56% | |
| FCO | 13.49 | -0.06 | -0.44% | |
| FCNCA | 166.83 | +1.83 | +1.11% | 1.715B |
| FCLF | 6.00 | +0.23 | +3.99% | 46.32M |